A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, First-In-Patient Study Of AJ201 To Evaluate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics In Adults With Spinal And Bulbar Muscular Atrophy (SBMA)
Latest Information Update: 30 May 2025
At a glance
- Drugs ALZ-002 (Primary)
- Indications X-linked bulbo-spinal atrophy
- Focus Adverse reactions; First in man
- Sponsors AnnJi Pharmaceutical
Most Recent Events
- 21 May 2025 Results presented in the AnnJi Pharmaceutical Media Release.
- 14 Nov 2024 According to Avenue therapeutics media release, company anticipated topline data from this trial around year-end 2024.
- 15 Aug 2024 Status changed from active, no longer recruiting to completed.